Clinical Research Directory

COHORT 1 Inclusion Criteria: * Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) regardless of the mutation status * Inclusion at the time of diagnostic * Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report * Age ≥ 18 years * Covered by a health insurance * Signed consent Exclusion Criteria: \- Patients treated before their liquid biopsy COHORT 2 Inclusion criteria * Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor Receptor (EGFR), B-Raf proto oncogene (BRAF) or Human Epidermal Growth Factor Receptor-2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS porto-oncogene 1 (ROS1) translocation, Mesenchymal-epithelial transition factor (MET) amplification, RET rearrangement. * Inclusion at the time of diagnosis * Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report * Age ≥ 18 years * Covered by a health insurance * Signed consent COHORT 3 Inclusion criteria * Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) whatever the mutational or PD-L1 status. * Inclusion at the time of immunotherapy treatment initiation (1st or 2nd line) * Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report * Age ≥ 18 years * Covered by a health insurance * Signed consent Exclusion criteria \- Initiation of immunotherpy before their liquid biopsy